Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pravastatin Adjunctive Therapy for Tuberculosis
NCT03456102Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2020
- Primary completion
- Aug 2022
- Countries
- 1
- Sponsor
- Johns Hopkins University
- Modality
- Small Molecules
- Drugs
- pravastatin
- Conditions
- Tuberculosis (TB)
01
Overview
Phase 2, open-label trial of pravastatin in Tuberculosis (TB), sponsored by Johns Hopkins University. Started Mar 2020; status: completed.
02
Design
- Study design
- Non-randomizedOpen-label
03
Registry description
There is an urgent need for novel therapies to shorten TB treatment and improve long-term lung function outcomes. Host-directed therapies (HDT) have received significant attention recently given the ability of M. tuberculosis to subvert host immune responses and cause destructive lung pathology. Statins are among the most promising HDT agents for TB. In addition to having a highly favorable safety profile, statins have been shown to have anti-TB activity in macrophages, to synergize with anti-TB drugs, and to shorten the duration of TB treatment in the standard mouse model.
The StAT-TB…
Beyond the preview
Go deeper on NCT03456102.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456102.